newsfilter
← Latest News
PR Newswire·

Ladera Medical Presents Full FASTEN Results Showing Rapid Hemostasis and a Strong Safety Profile with its Large Bore Closure System

  • Ladera Medical presented full FASTEN clinical trial results for the Ladera Large Bore Closure System (LBC) at London Valves 2026.
  • The prospective, multicenter, single-arm study enrolled 55 patients across six sites in Australia, Belgium, & the Netherlands.
  • The system achieved a mean time to hemostasis of 0.5 ± 2.0 minutes (median 0 minutes) in the common femoral artery.
  • Freedom from major access-site complications at 30 days was 98.1% (52/53).
  • Technical success was 94.5% (52/55) & treatment success was 94.3% (50/53).
  • Mean time to ambulation was 14.3 ± 14.5 hours.
  • The device is designed to close 10F to 24F arteriotomies with a single suture-mediated mechanism that deploys two parallel sutures.
  • The system allows for pre-close or post-close deployment while maintaining guidewire access.
  • The Ladera LBC System is restricted to investigational use by Federal law & is not available for sale.
Company
Ladera Medical, Inc / SPRIG CONSULTING, LLC
Keywords
Ladera Medical, Inc / SPRIG CONSULTING, LLC